Thermo Fisher Scientific (TMO)

As of 30 September 2026, short interest in TMO is 5,408,135 shares, down 282,453 shares over the last month. Over the last 48 readings it ranged from 2,933,571 shares (31 October 2024) to 5,690,588 shares (31 August 2026). At the reported average volume of 2.6M shares a day that is 2.1 days to cover.

<iframe src="https://xoomar.com/embed/stocks/tmo" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>

As of 9 October 2026, the short share of TMO volume is 36.9%, down 16.4 points over the last five sessions. Over the last 30 readings it ranged from 29.6% (8 October 2026) to 65.8% (15 September 2026). The latest reading is 11.7 points below the 30-session average of 48.6%, on 712K shares reported.

As of 9 September 2026, the fails-to-deliver balance in TMO is 90 shares, down 2,810 shares over the last settlement date. Over the last 30 readings it ranged from 4 shares (27 April 2026) to 58,527 shares (4 June 2026). The latest reading sits at the bottom of that range.

Insiders at TMO reported 93 open-market sells worth $61.6M in the last 90 days and no open-market buys. Latest filing: Pettiti Gianluca (President & COO) on 2026-08-31.

Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.

35 Form 144 notices on file for TMO worth $181.3M at the prices reported; 13 in the last 90 days worth $61.7M. Latest: Pettiti Gianluca filed on 2026-08-31 to sell 4,133 shares ($2.5M) from 2026-08-31.

1 holder reports 5% or more of TMO in its latest filing, on Schedule 13G (passive). The holder is Vanguard Capital Management at 7.5% of the class (28,008,822 shares), filed 2026-04-30 for an event on 2026-03-31.

10 of the 30 tracked managers held TMO at their latest 13F, $3.42B in total at quarter-end prices. Fisher Asset Management is the largest at $1.46B (0.4% of its portfolio) as of 2026-06-30. Over the prior quarter 6 added shares and 4 cut.

Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.

In Q2 FY 2026 (quarter ended 2026-06-27) Thermo Fisher Scientific reported revenue of $11.99B, up 10.5% from the same quarter a year earlier, and net income of $1.74B (4.68 diluted EPS). In FY 2025 it generated $7.82B of operating cash flow and spent $3.00B on buybacks and $636.0M on dividends. As of 2026-06-27, cash was $4.06B against $42.28B of debt.

Quarterly, last 8 quarters

Fiscal years, with buybacks and dividends

Quarters are the three-month figures the company reports; a fourth quarter marked derived is the fiscal year less the three reported quarters, since companies report it only inside the 10-K. Fiscal years are the annual figures. Buybacks are the cash the company paid to repurchase its common stock in the year, not the amount authorized. Balance sheet lines are as of 2026-06-27; shares outstanding as of 2026-06-27 from the cover page.